AMPLIFICATION OF CLINICAL EFFICACY
"Great pharmaceuticals arise through listening to ALL stakeholders"
At Amplio Pharma BV, we pursue the development of sustainable, innovative, value-added medicines
There is a clear unmet medical need in the treatment of immune-mediated inflammatory diseases (IMIDs), like Rheumatoid Arthritis, Plaque Psoriasis and Crohn's disease today with available drugs failing to successfully treat many of the patients to disease remission
OUR INNOVATIVE TECHNOLOGY
For more information, contact us today
For Methotrexate Forte (AMP101),
we use our proprietary modified retention solution,
to amplify the clinical effect of low dose Methotrexate, the no 1 treatment
in immune-mediated inflammatory diseases (IMIDs), that include Rheumatoid Arthritis, Plaque Psoriasis and Crohn's disease, affecting >20M patients annualy
OUR FOUNDERS
Charlott, Karin and Marguerite first met almost 25 years ago early in their careers.
Since then, they have moved through the pharmaceutical industry through different executive functions,
leading early hit-to-lead R&D to pipeline development to market access and pharmaceutical sales.
Together they share the know-how needed to identify an unmet medical need, develop a drug product that addresses said unmet medical need and successfully bring such a product to the market and into the hands of the patient
With our innovative and insightful technology, we strive to enhance patients’ every day quality of life.
Founded in 2020. Get in touch to learn more.
OUR ADVISORS
Henrik Fenger and Lars B Rasmussen both joined Amplio Pharma as advisors in 2022 adding their unique experience in marketing, liason management as well as finance within smaller pharmaceutical companies to the founders team
Prof. Tom W.J. Huizinga, who heads the Rheumatology department and Prof. Teun van Gelder, who heads the Academic Pharma group at the reknown LUMC in Leiden, the Netherlands, share a passion for sustainable and affordable pharmaceutical care. In addition, Teun is a leading ethicist is a member of the Dutch CCMO
PROJECT TEAM and PARTNERS for METHOTREXATE FORTE
For Methotrexate Forte to come on to the market, it has to go through a clinical development program
where it shows superiority over the current drug products with methotrexate. Because we have chosen our PK enhancer in a smart and sustainable way, we already know a lot about the clinical behavior of Methotrexate Forte and we have shown that in pre-clinical models, Methotrexate Forte delivers what it promises: an elongated elimination of methotrexate from the system!
​
Together with the Academic Pharma group of the LUMC, the phase 1 clinic of Leiden, the CHDR and the rheumatology group of the LUMC, we are now getting ready for the human proof-of-principle study, which will test the hypothesis of Methotrexate Forte in both healthy volunteers AND in patients
OUR INVESTORS
--
©2020 by Amplio Pharma BV. Proudly created with Wix.com